Previous 10 | Next 10 |
BioMarin Hires Pharmaceutical Industry Leaders in Marketing and Accounting to Fill Strategic Roles Supporting Company's Growth Plans PR Newswire Humaira Serajuddin Named to Newly Created Role of Senior Vice President, Chief Marketing Officer Erin Burkhart , Named...
BioMarin to Present Findings from Ongoing Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the World Federation of Hemophilia 2022 World Congress, May 8-11, 2022, Including Five Platform Presentations PR Newswire Ongoing Clinical Development Progra...
BioMarin to Participate in the BofA Securities 2022 Healthcare Conference, Thursday, May 12 at 8:40amPT/11:40amET PR Newswire SAN RAFAEL, Calif. , May 4, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques B...
BBH’s price multiples indicate an undervaluation and its major holdings have started recording significant price growth. BBH has strong fundamentals and has performed well enough in the medium and long term. BBH will face some minor ups and downs since most stocks are yet t...
BioMarin Pharmaceutical Inc. (BMRN) Q1 2022 Earnings Conference Call April 27, 2022 16:30 ET Company Participants Traci McCarty - Vice President, Investor Relations J.J. Bienaime - Chairman and Chief Executive Officer Jeff Ajer - Executive Vice President and Chief Commercial Officer Hank Fuch...
BioMarin Pharmaceutical press release (NASDAQ:BMRN): Q1 GAAP EPS of $0.63 beats by $0.39. Revenue of $519M (+6.8% Y/Y) beats by $9.69M. Full-year 2022 Financial Guidance for Voxzogo Net Product Revenues Increased to between $100 Million to $125 Million; Remaining Guidance Reaffirmed For fur...
BioMarin Announces Record Revenues in First Quarter 2022 PR Newswire BioMarin Reports Record First Quarter Total Revenues of $519 Million Driven by a $20 Million VOXZOGO Contribution; Total Revenues Grew 11% Year-over-Year, Excluding Kuvan Full-year 202...
BioMarin Pharmaceutical (NASDAQ:BMRN) Q1 consensus EPS estimate is $0.46 and consensus revenue estimate is $509.31M (+4.8% y/y). The pharmaceutical company will report Q1 results tomorrow, Apr. 27, after market close. Over the last 3 months, EPS estimates have seen 6 upward rev...
Reassessing its coverage on large cap biotech, Morgan Stanley upgraded BioMarin Pharmaceutical (NASDAQ:BMRN) on Monday, a commercial stage company focused on rare diseases and medical conditions. The analysts led by Matthew Harrison ague that BioMarin (BMRN), which has lost ~9% in the year so...
BioMarin to Host First Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, April 27, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , April 13, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Ja...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Pharmaceutical Inc. Website:
BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , July 23, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander ...
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-27 14:15:03 ET Scotiabank analyst issues UNDERPERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Underperform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus : BU...